Boston, MA, February 12, 2026 – Ampersand Capital Partners, a private equity firm specializing in growth investments in the life sciences and healthcare sectors, today announced its acquisition of Purna Pharmaceuticals, a trusted provider of development and manufacturing services for liquid and semi-solid dosage forms in support of pharmaceutical industry customers.
MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from Its Phase 3 Study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
DURHAM, N.C., March 17, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today welcomed the news that its partner, Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), recently announced positive topline results from its Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), an investigational therapy underdevelopment for the treatment of microcystic lymphatic malformations (microcystic LMs).